{"id":"hx008-tace","safety":{"commonSideEffects":[{"rate":null,"effect":"Immune-related adverse events (irAEs)"},{"rate":null,"effect":"Hepatotoxicity"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Nausea"}]},"_chembl":{"chemblId":"CHEMBL4650472","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"HX008, a humanized PD-1 monoclonal antibody, blocks the PD-1/PD-L1 checkpoint to reinvigorate T-cell-mediated anti-tumor immunity. When combined with TACE—a minimally invasive procedure that delivers chemotherapy directly to liver tumors while occluding their blood supply—the approach aims to synergize local tumor destruction with systemic immune activation, potentially improving outcomes in hepatocellular carcinoma.","oneSentence":"HX008 is a PD-1 inhibitor combined with TACE (transarterial chemoembolization) to enhance anti-tumor immunity while delivering localized chemotherapy to hepatic tumors.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:47:33.648Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hepatocellular carcinoma (HCC) in combination with transarterial chemoembolization"}]},"trialDetails":[{"nctId":"NCT05647954","phase":"PHASE3","title":"A Study of HX008 Plus Transcatheter Arterial Chemoembolization (TACE) in the First-Line Treatment of Subjects With Stage IV (M1c) Melanoma That is Metastatic to the Liver","status":"UNKNOWN","sponsor":"Taizhou Hanzhong biomedical co. LTD","startDate":"2022-12-31","conditions":"Melanoma Neuroendocrine Tumors Neuroectodermal Tumors Neoplasms Germ Cell and Embryonal Neoplasms by Histologic Type Neoplasms Neoplasms","enrollment":350}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"HX008 + TACE","genericName":"HX008 + TACE","companyName":"Taizhou Hanzhong biomedical co. LTD","companyId":"taizhou-hanzhong-biomedical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"HX008 is a PD-1 inhibitor combined with TACE (transarterial chemoembolization) to enhance anti-tumor immunity while delivering localized chemotherapy to hepatic tumors. Used for Hepatocellular carcinoma (HCC) in combination with transarterial chemoembolization.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}